Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TML-6, an oral curcumin derivative, demonstrates inhibitory effects on the synthesis of β-amyloid precursor protein and β-amyloid (Aβ). Additionally, TML-6 exhibits upregulation of Apo E, suppression of NF-κB and mTOR, and enhancement of the anti-oxidative Nrf2 gene activity. Considering its diverse pharmacological profile, TML-6 holds promise as a valuable research tool for investigating Alzheimer's disease (AD)[1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,540 | 5日内发货 | ||
5 mg | ¥ 2,610 | 5日内发货 | ||
25 mg | ¥ 9,930 | 6-8周 | ||
50 mg | ¥ 12,900 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | TML-6, an oral curcumin derivative, demonstrates inhibitory effects on the synthesis of β-amyloid precursor protein and β-amyloid (Aβ). Additionally, TML-6 exhibits upregulation of Apo E, suppression of NF-κB and mTOR, and enhancement of the anti-oxidative Nrf2 gene activity. Considering its diverse pharmacological profile, TML-6 holds promise as a valuable research tool for investigating Alzheimer's disease (AD)[1]. |
体外活性 | TML-6 (0.65-5.24 μg/mL; for 24 h) reduces the protein expression levels of APP and phospho-NF-κB, and induces the protein expression level of ApoE. TML-6 inhibits the mTOR signaling pathway through the suppression of phospho-mTOR[1]. TML-6 (0.31, 0.63, 2.5, 5, 10, 20 μM; 24 h) reveals no cytotoxicity in Huh-7 cells at concentrations below 5 μM and has an IC50 of 4.19 μg/mL (8 μM)[1]. TML-6 (1.05, 2.09, 3.14, 4.19 μg/mL; 24 h) reduces the production of Aβ40 and Aβ42 between 1.05, 2.09 and 3.14 μg/mL (equal to 2, 4 and 6 μM) in a dose-dependent manner in N2a/APPswe cell[1]. TML-6 can exhibit transcriptional activation of the Nrf2 gene in a dose-dependent manner, with the highest activity at a concentration of 1.32 μg/mL[1]. |
体内活性 | TML-6 (diet; 150 mg/kg/day; for four months) treatment results in significant improvement in learning, suppression of the microglial activation marker Iba-1, and reduction in Aβ in the brain[1]. TML-6 (oral; 150 mg/kg) has a T1/2 of 1.27 hours, a Cmax of 35.9 ng/mL and an AUC of 177 ng?hr/mL[1]. |
分子量 | 523.62 |
分子式 | C30H37NO7 |
CAS No. | 1462868-88-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 120 mg/mL (229.17 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9098 mL | 9.5489 mL | 19.0978 mL | 47.7445 mL |
5 mM | 0.382 mL | 1.9098 mL | 3.8196 mL | 9.5489 mL | |
10 mM | 0.191 mL | 0.9549 mL | 1.9098 mL | 4.7745 mL | |
20 mM | 0.0955 mL | 0.4774 mL | 0.9549 mL | 2.3872 mL | |
50 mM | 0.0382 mL | 0.191 mL | 0.382 mL | 0.9549 mL | |
100 mM | 0.0191 mL | 0.0955 mL | 0.191 mL | 0.4774 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TML-6 1462868-88-7 TML6 TML 6 Inhibitor inhibitor inhibit